Word

BIBAX

Status

Pending

Status Code

653

Status Date

Wednesday, January 31, 2024

Serial Number

97766160

Mark Type

4000

Filing Date

Tuesday, January 24, 2023

Trademark Owner History

de la Rosa, Kathrin

Classifications

5 Medical and veterinary preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment and prevention of human infectious diseases; biomedical pharmaceutical products for the treatment and prevention of human infectious diseases; clinical diagnostic reagents; therapeutic agents being Therapeutic vaccines; prophylactical agent substances, namely, pharmaceutical preparations for the prevention of infectious diseases; medicine being Medicinal preparations for the treatment of infectious diseases and for use in; biological and chemical reagents, for medical and veterinary uses; agonists for medical and veterinary uses, namely, namely, pharmaceutical preparations for the treatment and prevention of human infectious diseases; medicines for veterinary purposes for the treatment and prevention of infectious diseases; amino acids for medical or veterinary purposes; antibacterial pharmaceuticals; anti-bacterial preparations; antibacterial substances for medical purposes; antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; antibodies, namely, monoclonal antibodies for in vivo or clinical use; antitoxins; antiviral drugs for treating influenza; antiviral drugs for treating hiv; anti-viral agents, namely, anti-viral antigens being pharmaceutical preparations for the treatment and prevention of infectious diseases; autoantigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; biological adjuvants for medical purposes; endogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; exogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; human immune globulin for the treatment and prevention of cancer and infectious diseases; human vaccine preparations; immunomodulators; immunostimulants; vaccines against flu; immunotherapeutic agents for bacterial infections; anti-infective goods for medical and veterinary uses; medicated mouth spray; medicated nasal spray preparations; anti-malarials; neoantigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical products for treating respiratory diseases, pharmaceutical products for the treatment of infectious diseases, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of disorders caused by bacteria, pharmaceutical preparations for the treatment of diseases caused by bacteria, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of disorders of the immune system; anti-infectives; anti- tuberculous preparations; tumour antigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; viral antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; viral vaccines; veterinary vaccines; vaccines; mrna and vector-based vaccines; protein-based vaccines

42 Provision of information and data in the field of medical and veterinary research and development, namely, in the fields of immunology, infectiology and vaccines; research and design for the pharmaceutical industry, namely in the fields of immunology, infectiology and vaccines; biomedical research services; research and development in the field of vaccines; software development and research in the fields of infectiology and immunology; research and development of biomolecules, cells and cell products for medical purposes; research and development of biomedical goods, in particular therapeutic and prophylactic substances, namely, pharmaceuticals for medical purposes, and preparations for the treatment of Coronaviridae, including SARS-CoV-2 and MERS-CoV, Flaviviridae including Dengue, hepatitis, yellow fever, and Zika virus, Herpesviridae including EBV, Orthomyxoviridae including Influenzaviruses, and Filoviridae; medical laboratory services; computer diagnostic services

Trademark Events

Jan 31, 2024

Notification Of Letter Of Suspension E-Mailed

Jan 31, 2024

Letter Of Suspension E-Mailed

Jan 31, 2024

Suspension Letter Written

Jan 26, 2024

Teas/Email Correspondence Entered

Jan 25, 2024

Correspondence Received In Law Office

Jan 25, 2024

Teas Response To Office Action Received

Oct 25, 2023

Notification Of Non-Final Action E-Mailed

Oct 25, 2023

Non-Final Action E-Mailed

Oct 25, 2023

Non-Final Action Written

Oct 21, 2023

Assigned To Examiner

Feb 13, 2023

New Application Office Supplied Data Entered

Jan 27, 2023

New Application Entered